🔥36氪•Feb 25, 2026Stalecollected in 5m

AI Biopharma BD Deals Heat Up in 2026

Post LinkedIn

🔥Read original on 36氪

#ai-biotech#bd-licensing#bci-ipoinsilico-medicineinsilico-medicineastrazenecaneucyber

💡AI drug startups at $3B vals snag 50% global BD—prime opps for AI biotech devs.

⚡ 30-Second TL;DR

What Changed

100+ medical firms in HK IPO queue; Pre-IPO rounds hedge market risks at $3-5B vals.

Why It Matters

Validates AI acceleration in drug discovery, opening BD/partnership paths for AI platforms in underserved therapeutic areas. Signals investor maturity favoring proven out-licensing over hype.

What To Do Next

Target MNC BD for your AI-generated CNS or metabolism candidates using Insilico-like platforms.

Who should care:Founders & Product Leaders

Key Points

•100+ medical firms in HK IPO queue; Pre-IPO rounds hedge market risks at $3-5B vals.
•China BD deals claim 50% global share, MNCs enthusiastic but note rising prices.
•AI pharma like Insilico lands deals; one startup valued at $3B USD.
•BCI frenzy with Neucyber, Qiangnao Tech rushing IPOs; valuations over $4.5B.
•Hot non-tumor areas: autoimmunity, metabolism, CNS; GLP-1 iterations focus on oral forms.

🧠 Deep Insight

Background and context from public sources — not the original article. 9 sources cited.

🔑 Enhanced Key Takeaways

•Insilico Medicine listed on the Hong Kong Stock Exchange in December 2025, raising approximately $290-293 million USD.[1][4][5][9]
•Insilico secured a collaboration with Servier in early 2026 for oncology drug discovery using Pharma.AI, with total potential value up to $888 million including $32 million upfront and early milestones.[5]
•Insilico received a $5 million milestone payment from Menarini in late 2025 or early 2026 for first-in-patient dosing in Phase 1 of MEN2501 (ISM9682), a KIF18A inhibitor for cancers with chromosome instability.[6]
•Insilico has software licensing agreements with 13 of the world's top 20 multinational pharmaceutical companies, alongside research collaborations with Fosun Pharma and Sanofi involving upfront payments of tens of millions.[2][3][7]

🔮 Future ImplicationsAI analysis grounded in cited sources

Insilico's Pharma.AI platform will secure at least two additional out-licensing deals exceeding $100 million by end of 2026

The company's recent deals with Qilu ($120M), Servier ($888M), and prior out-licensing totaling over $2B with Exelixis and Menarini demonstrate accelerating momentum in AI-driven partnerships.[2][5]

AI biopharma BD deals in China will exceed 60% global market share by mid-2026

China already claims 50% of global BD deals with rising MNC interest and valuations, fueled by firms like Insilico achieving frequent high-value partnerships.[1][2]

⏳ Timeline

2021

Qilu begins using Insilico’s PandaOmics platform, laying groundwork for expanded collaboration.[3]

2025-01

Insilico out-licenses ISM9682 (MEN2501) to Menarini Group.[6]

2025-07

Insilico receives $3 million development milestone from Menarini.[6]

2025-12

Insilico Medicine lists on Hong Kong Stock Exchange, raising ~$290M.[1][4][5][9]

2026-01

Insilico signs $888M oncology collaboration with Servier using Pharma.AI.[5]

2026-01

Insilico and Qilu announce $120M partnership for cardiometabolic small molecule inhibitors.[2][3][7]

📎 Sources (9)

Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.

🔥Read original article on 36氪

📰

Weekly AI Recap

Read this week's curated digest of top AI events →

👉Related Updates

Same topic

Explore #ai-biotech

Same product